Treatment of subclinical hypothyroidism linked with fewer ischemic heart events in younger patients

April 23, 2012

Treatment of subclinical hypothyroidism with the medication levothyroxine appears to be related to fewer ischemic heart disease events in younger patients but this finding was not evident in older patients, according to a report published Online First in Archives of Internal Medicine.

Subclinical hypothyroidism (SCH) is defined as an elevated serum thyrotropin level in the presence of normal concentrations. The condition is relatively common and often asymptomatic, although recent meta-analyses have suggested that SCH is associated with increased cardiovascular events and death, especially in young to middle-aged adults, the authors write in their study background. But those epidemiologic associations do not prove that treatment of SCH would be effective, the authors note.

"Thus, only adequately powered randomized controlled intervention trials will be able to demonstrate whether treatment of SCH is worthwhile in terms of improvement in both and symptoms. However, such a trial has not been performed to date and no such trials are ongoing," they comment.

Salman Razvi, M.D., F.R.C.P., of Gateshead Health Foundation Trust and Newcastle University, England, and colleagues used the United Kingdom General Practitioner Research Database to indentify patients with new SCH recorded during 2001 with outcomes analyzed until March 2009. SCH was identified in 3,093 younger patients (40-70 years) and 1,642 older patients (older than 70 years). Levothyroxine was used to treat 52.8 percent of younger patients and 49.9 percent of older patients.

The study results indicate there were 68 incident IHD events among 1,634 younger patients treated with levothyroxine (4.2 percent) vs. 97 events among 1,459 untreated individuals (6.6 percent). In the older group there were 104 events among 819 treated patients (12.7) percent vs. 88 events among 823 untreated patients (10.7 percent).

"In conclusion, treatment with was associated with fewer IHD events and reduced all-cause mortality during an eight-year period of observation in 40 to 70-year-old individuals with SCH but not in those who were older. A prospective randomized controlled trial is required to confirm these findings," the authors conclude.

Explore further: Concern over 'excessive' doses of thyroid drugs for older patients

More information: Arch Intern Med. Published online April 23, 2012. doi:10.1001/archinternmed.2012.1159

Related Stories

Recommended for you

Monkeys in Asia harbor virus from humans, other species

November 19, 2015

When it comes to spreading viruses, bats are thought to be among the worst. Now a new study of nearly 900 nonhuman primates in Bangladesh and Cambodia shows that macaques harbor more diverse astroviruses, which can cause ...

One-step test for hepatitis C virus infection developed

November 14, 2015

UC Irvine Health researchers have developed a cost-effective one-step test that screens, detects and confirms hepatitis C virus (HCV) infections. Dr. Ke-Qin Hu, director of hepatology services, will present findings at the ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.